There is certain evidence that treatments designed to control parathyroid hormone (PTH), Ca and P levels in patients with advanced CKD such as calcimimetics and phosphate binders may attenuate calcification progression in HD patients with secondary hyperparathyroidism [34–38]. The gene discussed is PTH; the disease is secondary hyperparathyroidism.